SCHEMBL6085149

SCHEMBL6085149

Cc1ccc(C(C)C)c2oc(-c3c[nH]nc3-c3cccc(NC(=O)c4cc5ccccc5oc4=O)c3)nc12

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAOB P27338 17/20 0.49
MAOA P21397 12/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
ADORA3 P0DMS8 1/20 0.49
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
KMT2A Q03164 1/20 0.45
PTK2B Q14289 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
F12 P00748 1/20 0.45
MITF O75030 1/20 0.44
ALDH1A1 P00352 1/20 0.44
XBP1 P17861 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6085153 0.86 MAOB (0.49) MAOBMAOA
SCHEMBL6084819 0.86 ALDH1A1 (0.44) RAB9ANPC1POLBMAPTKMT2A
SCHEMBL6085797 0.86 NPC1 (0.42) RAB9ANPC1POLBMAPTKMT2A
SCHEMBL6084903 0.82 MEN1 (0.44) NPC1POLBMAPTKMT2ASMN1; SMN2
SCHEMBL6086056 0.81 POLB (0.44) RAB9ANPC1ADORA3POLBSMN1; SMN2
SCHEMBL6086423 0.81 TSHR (0.46) RAB9ANPC1ADORA3POLBKMT2A
SCHEMBL6087407 0.81 MAOB (0.58) MAOBMAOARAB9ANPC1ADORA3
SCHEMBL6085475 0.81 MAPT (0.59) MAOBMAOARAB9ANPC1ADORA3
SCHEMBL6085763 0.81 TP53 (0.37) RAB9ANPC1POLBMAPTKMT2A
SCHEMBL6086910 0.78 HSP90AA1 (0.39) RAB9ANPC1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 MAOB 3795/4885MAOA 3967/4885RAB9A 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.